Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology

Rodolfo Savica, Melissa E. Murray, Xuan Mai Persson, Kejal Kantarci, Joseph E. Parisi, Dennis W. Dickson, Ronald C. Petersen, Tanis J. Ferman, Bradley F. Boeve, Michelle M. Mielke

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Introduction: The clinical and pathological phenotypes of Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) often overlap. We examined whether plasma lipids differed among individuals with autopsy-confirmed Lewy Body pathology or AD pathology. Methods: We identified four groups with available plasma 2 years before death: high (n = 12) and intermediate-likelihood DLB (n = 14) based on the third report of the DLB consortium; dementia with Alzheimer's pathology (AD; n = 18); and cognitively normal with normal aging pathology (n = 21). Lipids were measured using ESI/MS/MS. Results: There were overall group differences in plasma ceramides C16:0, C18:1, C20:0, and C24:1 and monohexosylceramides C18:1 and C24:1. These lipids did not differ between the high-likelihood DLB and AD groups, but both groups had higher levels than normals. Plasma fatty acid levels did not differ by group. Discussion: Plasma ceramides and monohexosylceramides are elevated in people with dementia with either high-likelihood DLB or AD pathology.

Original languageEnglish (US)
Pages (from-to)43-50
Number of pages8
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
StatePublished - 2016
Externally publishedYes


  • Alzheimer's disease
  • Autopsy
  • Ceramide
  • Lewy body
  • Lipids

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology


Dive into the research topics of 'Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology'. Together they form a unique fingerprint.

Cite this